C. Bunchorntavakul and K. R. Reddy. Herbal and dietary supplement hepatotoxicity:3–17 (Review article)

del Campo JA, Ampuero J, Rojas L, Conde M, Rojas Á, Maraver M, et al. Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism:74–80

Hu C-C, Lin C-L, Kuo Y-L, Chien C-H, Chen S-W, Yen C-L, et al.  Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C:81–90

Berry PA, Thomson SJ, Rahman TM, Ala A. Towards a considered and ethical approach to organ support in critically-ill patients with cirrhosis:174–182 (Review article)

Houlihan DD, Holt A, Elliot C, Ferguson JW. Liver transplantation for the pulmonary disorders of portal hypertension:183–194 (Review article)

Chen T-M, Chang C-C, Huang P-T, Wen C-F, Lin C-C. Performance of Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients:243–251